Skip to Content

Stoke Therapeutics Inc STOK

Morningstar Rating
$14.17 +3.88 (37.71%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

STOK is trading at a 64% discount.
Price
$6.44
Fair Value
$13.67
Uncertainty
Extreme
1-Star Price
$951.79
5-Star Price
$2.73
Economic Moat
Mssr
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if STOK is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$10.29
Day Range
$10.3516.40
52-Week Range
$3.3516.40
Bid/Ask
$14.55 / $14.79
Market Cap
$632.74 Mil
Volume/Avg
56,609 / 982,504

Key Statistics

Price/Earnings (Normalized)
Price/Sales
71.00
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
110

Comparables

Valuation

Metric
STOK
CELC
ELVN
Price/Earnings (Normalized)
Price/Book Value
4.084.373.13
Price/Sales
71.00
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
STOK
CELC
ELVN
Quick Ratio
6.5410.549.78
Current Ratio
6.9911.1510.28
Interest Coverage
−12.62
Quick Ratio
STOK
CELC
ELVN

Profitability

Metric
STOK
CELC
ELVN
Return on Assets (Normalized)
−31.45%−35.89%−24.03%
Return on Equity (Normalized)
−43.11%−50.02%−29.30%
Return on Invested Capital (Normalized)
−47.87%−39.18%−35.22%
Return on Assets
STOK
CELC
ELVN
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRBlhbwyvhmLpkt$571.0 Bil
VRTX
Vertex Pharmaceuticals IncHjpnnngxzPfzppm$107.8 Bil
REGN
Regeneron Pharmaceuticals IncNrlktgsjgRjphsrr$106.1 Bil
MRNA
Moderna IncStzmvwlVsnr$42.3 Bil
ARGX
argenx SE ADRKtfbzzpxDxggf$23.7 Bil
BNTX
BioNTech SE ADRLmkkrlwKhbwk$22.1 Bil
ALNY
Alnylam Pharmaceuticals IncMspstkjtYgfhbp$19.4 Bil
BMRN
Biomarin Pharmaceutical IncFplxqjlXydqt$16.7 Bil
RPRX
Royalty Pharma PLC Class AJqfztbjxypXhszw$13.6 Bil
INCY
Incyte CorpDswntjcBffmgx$12.8 Bil

Sponsor Center